By Marie Rosenthal
Originally published by our sister publication Infectious Disease Special Edition
In two votes, one for the Moderna and the other for the Pfizer-BioNTech bivalent boosters, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted overwhelmingly—if somewhat reluctantly—to recommend the use of the bivalent COVID-19 messenger RNA (mRNA) boosters to replace the monovalent boosters. The FDA had granted an emergency use authorization for the bivalent